Novel quinolines carrying pyridine, thienopyridine, isoquinoline, thiazolidine, thiazole and thiophene moieties as potential anticancer agents
to the World Health Organization (WHO), unless further preventive measures are put into practice (1) . Quinoline scaffold plays an important role in anticancer drug development since their derivatives have shown excellent results through different mechanisms of action such as growth inhibition by cell cycle arrest, apoptosis, inhibition of angiogenesis, disruption of cell migration and modulation of nuclear receptor responsiveness. The anticancer potential of several of these derivatives has been demonstrated on various cancer cell lines. In addition, many of quinoline derivatives are useful in diverse applications including pharmaceuticals and are today available as drugs (2) . Therefore there is an urgent need to develop new classes of chemotherapeutic agents with different mechanisms of action to treat cancer (3) . It has been reported that designing a single molecule with more than one pharmacophore with different modes of action could be beneficial for the treatment of cancer (4) , as well as for reducing unwanted side effects (5) . Many quinolines, dihydropyridines, thienopyridines, isoquinolines, acrylamides, thiazolidines, thiazoles and thiophenes were found to possess antineoplastic activity (6) (7) (8) (9) (10) (11) . Although the antineoplastic activity of these quinolines was attributed to intercalating binding to DNA, there were additional advantages of quinolines that interact with DNA, with a low association constant. The corresponding significant increase in the amount of free drug at equilibrium may have an important effect upon the distribution and hence the spectrum of activity and ac ces sibility of these molecules to solid tumors (12, 13) . On the other hand, a number of quinoline derivatives were reported to reverse tumor cell multidrug resistance (14, 15) . Recently, it has been demonstrated that 10 μmol L -1 chloroquine significantly increases cancer cell killing effects (4, 16) . Several chloroquinolines (CQ) known as antimalarial drugs, such as -diethylpentane-1,4-diamine (IV) and N 4 -(6-metho xyquinolin-8-yl) pentane-1,4-diamine (primaquine, PQ, V) ( Fig. 1 ) have been examined as cytotoxic agents against the MCF7 breast cancer cell line. Some of these compounds were very effective (17) . It has been reported that CQ and its analogs have a unique property of being accumulated in the lysosomes, raising intralysosomal pH, and resulting in enhancement of cell killing by cancer therapeutic agents in a variety of different tumors (18) . It is well known that many 2-pyridone derivatives revealed diverse biological activities such as anticancer (19) , cardiotonic (20) , and potential HIV1 specific reverse transcriptase inhibiting (21) . In view of the above mentioned findings and as a part of our research efforts to explore novel anticancer heterocyclic compounds (22) (23) (24) (25) (26) (27) (28) , we have synthesized a new series of quinoline derivatives carrying a number of biologically active moieties as analogues to compounds I-V (Fig. 1) .
EXPERIMENTAL
Melting points were uncorrected and determined in an open capillary on a Gallen Kamp melting point apparatus (Sanyo Gallen Kamp, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. A developing solvent system of chloroform/methanol (8:2) was used and the spots were detected by UV light. IR spectra (KBr disc) were recorded using an FT-IR spectrophotometer (Perkin Elmer, USA). 1 H NMR spectra were scanned on a NMR spectrophotometer (Bruker AXS Inc., Switzerland) operating at 500 MHz for 1 H-and 125.76 MHz for 13 C. Chemical shifts are expressed in d-values (ppm) relative to TMS as an internal standard, using DMSO-d 6 as a solvent. Elemental analyses were done on a model 2400 CHNSO analyzer (Perkin Elmer, USA). All the values were within ± 0.4 % of the theoretical values. All reagents used were of analytical grade. The starting material 3-aminoquinoline was purchased from Sigma (USA) and was directly used for the preparation of target compounds. (1) . -A mixture of quinolin-3-amine (1.44 g, 0.01 mol) and ethyl cyanoacetate (1.13 g, 0.01 mol) was fused at 220 °C for 2 h. The reaction mixture was cooled and the obtained product was crystallized from ethanol to give 1. (4) . -A mixture of compound 1 (2.1 g, 0.01 mol) and acetylacetone (5 mL) containing piperidine (0.5 mL) was fused for 6 h. The reaction mixture was cooled and the obtained solid was recrystallized from dioxane to give 4. [3,4-c] pyridine-4(5H)-one (5) . -A mixture of 4 (2.75 g, 0.01 mol) and elemental sulfur (0.32 g, 0.01 mol) in absolute ethanol (30 mL) containing 3 drops of triethylamine was refluxed for 8 h. The obtained solid was crystallized from dioxane to give 5. (20) . General procedure. -A mixture of 4 (2.75 g, 0.01 mol) and the respective benzylidenemalononitrile (0.01 mol) in ethanol (20 mL) containing a catalytic amount of piperidine (0.5 mL) was refluxed for 6 h. The obtained solid was filtered and crystallized from dioxane to give 6-20, respectively (Scheme 1, Table I ). (21) . -Dimethylformamide-dimethylacetal (1.19 g, 0.01 mol) was added to a solution of 1 (2.11g, 0.01 mol) in dry xylene (20 mL). The reaction mixture was refluxed for 8 h, cooled and the obtained solid was recrystallized from ethanol to give 21.
Syntheses 2-Cyano-N-(quinolin-3-yl)acetamide
4,6-Dimethyl-2-oxo-1-(quinolin-3-yl)-1,2-dihydropyridine-3-carbonitrile
3-Amino-6-methyl-5-(quinolin-3-yl)thieno

8-Amino
-3-methyl-1-oxo-6-phenyl-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (6), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-p-tolyl-1,2-dihydroisoquinoline-7-carbonitrile (7), 8-amino-6-(4-hydroxyphenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (8), 8-amino-6-(4-methoxyphenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-car-bonitrile (9), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-stryl-1,2-dihydroisoquinoline-7-carbonitrile (10), 8-amino-6-(2-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydro isoquinoline-7-car bo- nitrile (11), 8-amino-6-(4-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline- 7-carbonitrile (12), 8-amino-6-(4-(dimethylamino)phenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-di- hydroisoquinoline-7-carbonitrile (13), 8-amino-6-(benzo[d][1,3]dioxol-5-yl)-3-methyl-1-oxo-2- (quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (14), 8-amino-3-methyl-6-(3-nitrophenyl)-1- oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (15), 8-amino-3-methyl-6-(4- nitrophenyl)-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (16), 8-amino-6-(2,4- dichlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (17), 8-amino-6-(2-methoxynaphthalen-1-yl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline- 7-carbonitrile (18), 8-amino-6-(4-methoxynaphthalen-1-yl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1, 2-dihydroisoquinoline-7-carbonitrile (19), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-(thiophen-2- yl)-1,2-dihydroisoquinoline-7-carbonitrile
2-Cyano-3-(dimethylamino)-N-(quinolin-3-yl)acrylamide
2-(4-Oxothiazolidin-2-ylidene)-N-(quinolin-3-yl) acetamide (22)
. -A mixture of 1 (2.11 g, 0.01 mol) and 2sulfanylacetic acid (0.92 g, 0.01 mol) in dry pyridine (10 mL) was refluxed for 18 h. The reaction mixture was cooled and poured into ice/water. The obtained solid was recrystallized from acetic acid to give 22. (29) . General procedure. -To a suspension of 1 (2.11 g, 0.01 mol) in absolute ethanol (20 mL), finely divided sulfur (0.32 g, 0.01 mol), 3 drops of triethylamine, aryl isothiocyanate (0.01 mol) and DMF (10 mL) were added. The reaction mixture was stirred at 60 °C for 6 h, then left to cool at room temperature. The separated product was filtered, washed with ethanol, dried and crystallized from DMF/ethanol (2:1) to give 23-29, respectively.
4-Amino
-3-phenyl-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (23), 4-amino-N-(quinolin-3-yl)-2-thioxo-3-p-tolyl-2,3-dihydrothiazole-5-carboxamide (24), 4-amino- 3-(4-fluorophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (25), 4-amino- 3-(4-methoxyphenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (26), 4-ami- no-3-(4-nitrophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (27), 4-amino-3-(4-bromophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (28), 4-amino-3-(4-iodophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide
2-Amino
-To a solution of 1 (2.11 g, 0.01 mol) in absolute ethanol (30 mL), morpholine (1 mL), cyclopentanone or cyclohexanone and/or cycloheptanone (0.01 mol) and sulfur (0.32 g, 0.01 mol) were added. The reaction mixture was refluxed for 8 h. The separated product was filtered, dried and crystallized from dioxane to give 33-35, respectively. Physicochemical and spectral data are given in Tables I and II and synthetic pathways in Schemes 1 and 2. 
In vitro antitumor activity
The cytotoxic activity in vitro of the newly synthesized compounds was evaluated using the sulforhodamine B stain (SRB) assay and the method of Skehan (29) . The human breast cancer cell line (obtained from the National Cancer Institute, Cairo, Egypt) was maintained at 37 °C in 5 % CO 2 as subconfluent monolayers in 80 cm 3 culture flasks (Nunclon, Sigma, USA) and was subcultured once or twice weekly in Dulbecco's modification of Eagle in an atmosphere of 5 % CO 2 . Fortyeight hours after drug addition, cells were fixed with 50 % trichloroacetic acid at 4 °C (50 μL per well) for 1 h, washed with 1 % acetic acid and stained for 30 min with 50 μL of 0.4 % (m/V) sulphorhodamine (SRB) dissolved in 1 % ace- In vitro cytotoxic activity of the newly synthesized compounds 1, 4-29, 33-35 NA -no activity observed under experimental conditions. tic acid. Excess unbound dye was removed by four washes with 1 % acetic acid and the attached stain was recovered with TrisEDTA buffer. Colour intensity was measured using an enzyme-linked immunosorbent assay ELISA reader (BMG LABTECH GmbH, Germany). Absorbance was measured at 510 nm. The relation between the surviving fraction and drug concentration was plotted to get the survival curve for the breast cancer cell line (MCF7) after specified time (29) . The molar concentration required for 5 % inhibition of cell viability (IC 50 ) was preliminarily calculated from the constructed dose-response curve using the Prism software (Graphpad, Inc., La Jolla, USA) and the results are presented in Table III .
RESULTS AND DISSCUSION
Chemistry
Schemes 1 and 2 outline the synthetic pathways used to obtain compounds 1-35. The solvent-free reaction of aryl amines with ethyl cyanoacetate is well known as one of the most widely used synthetic methods. Thermal fusion of 3-aminoquinoline with ethyl cyanoacetate at 220 °C afforded the corresponding 2cyanoN-(quinolin-N-3-yl)acetamide (1). The structure of novel compounds was established on the basis of elemental analysis and spectral data. IR spectrum of compound 1 showed bands at 3260 cm -1 NH, and 2201 cm -1
C≡N, while
1 H-NMR spectrum revealed a singlet at 4.0 ppm assigned to the CH 2 group. In addition, the structure of compound 1 was confirmed through Xray crystallography (30) (Figs. 2 and 3 ).
The present study was aimed to prepare novel quinolone derivatives using cyanoacetamide 1 as strategic starting material. Thus, interaction of compound 1 with acetylacetone furnished the corresponding 4,6-dimethyl-2-oxo-1-(quinolin-3-yl)-1,2-dihydropyridine-3-carbonitrile 4. It can be postulated that the reaction initially proceeded via a nucleophilic attack to form Michael adduct 2 which in turn cyclized to product 3. Elimination of two molecules of water gave 1,2-dihydropyridine 4. IR spectrum of 4 showed the absence of NH 2 group and the presence of bands at 2937 and 2870 cm -1 (CH aliphatic), 2218 cm NMR spectrum showed signals at 1.6 ppm for CH 3 , 5.1 ppm for pyridinone CH, and 6.6 ppm for thiophene CH. 13 C NMR spectrum revealed a singlet at 161.2 ppm assigned to C=O. Application of Michael addition of 4 to benzylidinemalononitriles in absolute ethanol in the presence of piperidine yielded the corresponding 1,2-dihydroisoquinoline derivatives 6-20, via loss the of HCN molecule (Scheme 1). IR spectra of compounds 6-20 revealed the presence of bands for NH 2 , C≡N, C=O and C=N. 1 H NMR spectra of compounds 6-20 exhibited a singlet at 6.2-4.4 ppm assigned to the NH 2 group. Treatment of 1 with dimethylformamidedimethylacetal (DMF-DMA) in dry xylene gave the corresponding enamine derivative 21. IR spectrum showed bands at 3287 cm -1 (NH), 2224 cm -1 (C≡N), and 1688 cm -1 (C=O).
1 H NMR spectrum revealed signals at 2.6 ppm for N(CH 3 ), 7.5 ppm for the CH group and 8.9 ppm for the NH group. Interaction of compound 1 with 2-sulfanylacetic acid in pyridine produced the corresponding thiazolidine derivative 22. Compound 22 was characterized by the presence of a strong absorption band at 1705 cm -1 in the IR spectrum specific for the thiazolidinone as a proof of cyclization. In the 1 H NMR spectrum, it was the presence of a singlet equivalent to two protons at 3.7 ppm, representing the C-5 protons of the thiazolidinone nucleus. The group. 13 C NMR spectra of compounds 23-29 revealed signals at 189.6-183.9 ppm for C=S groups.
Finally, the corresponding thiophene derivatives 33-35 were obtained via the reaction of 1 with cyclopentanone or cyclohexanone and/or cycloheptanone and sulfur in a mixture of DMF/EtOH containing a catalytic amount of morpholine. The reaction may be explained via the intermediates 30-32 (Scheme 2). Their IR spectra revealed bands at 3420-3176 cm ). The quinoline derivative carrying dihydrothiazole with 4-nitrophenyl and thioxo moiety (27) , dihydrothiazole with 4fluorophenyl and thioxo moiety (25) , tetrahydrobenzothiophene (34), dihydroisoquinoline with 4-methylphenyl and carbonitrile moiety (7), tetrahydro-4-H-cycloheptathiophene (35), dihydroisoquinoline with unsubstituted phenyl moiety (6), acrylamide moiety (21), dihydroisoquinoline with 2-chlorophenyl moiety (11), dihydroisoquinoline with 4-hydroxyphenyl moiety (8) with exhibited good cytotoxic activity better than doxorubicin as reference drug (IC 50 26.7 to 44.7 μmol L -1 ). A closer look into the structure activity relationship indicates that addition of dihydrothiazole with thioxo group at 2-position, 4-nitrophenyl at 3-position, free amino group at 4-position, dihydrothiazole with thioxo group at 2position, 4fluorophenyl at 3position, free amino group at 4position and tetrahydrobenzo[b]thiophene with free amino group at 2-position was proven to be successful in the case of compounds 27, 25 and 34, which showed an increase in activity. Also, quinolone incorporating tetrahydrobenzo [b] thiophene (34) ). On the other hand, compounds 5, 9, 10, 24 and 33 exhibited moderate activity. Compounds 1, 4, 18 and 20 were the least active compounds in this series compared to doxorubicin, while the remaining compounds revealed no activity.
CONCLUSIONS
The objective of the present study was to synthesize and investigate the anti-breast cancer activity of some novel quinoline derivatives bearing biologically active moieties. All the synthesized compounds were characterized and evaluated for their anti-breast cancer activity and it was found that 4-amino-3-(4-nitrophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (27) , 4amino3(4fluorophenyl)N-(quinolin-3-yl)-2-thioxo-2, 3-dihydrothiazole-5-carboxamide (25), 2-amino-N-(quinolin-3-yl)-4,5,6,7-tetrahydrobenzo[b] thiophene-3-carboxamide (34), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-p-tolyl-1,2-dihydro isoquinoline-7-carbonitrile (7), 2-amino-N-(quinolin-3-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b] thiophene-3-carboxamides (35), 8-amino-3-methyl-1-oxo-6-phenyl-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (6), 2-cyano-3-(di methyl amino)-N-(quinolin-3-yl)acrylamide (21), 8-amino-6-(2-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (11) and 8-amino-6-(4-hydroxyphenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (8) exhibited anti-breast cancer activity higher than the positive control doxorubicin. Also, it was found that 8-amino-6-(4-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (12), 4-amino-3-(4-bromophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (28) , and 8-amino-3-methyl-6-(3-nitrophenyl)-1-oxo-2-(quinolin-3-yl)-1, 2-dihydroisoquinoline-7-carbonitrile (15) are almost as active as doxorubicin.
